SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Tuesday reported a loss of $72.4 million in its fourth quarter.

On a per-share basis, the San Diego-based company said it had a loss of $1.83.

The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.50 per share.

The biopharmaceutical company posted revenue of $526,000 in the period.

For the year, the company reported that its loss widened to $212.8 million, or $5.69 per share. Revenue was reported as $3.3 million.

Mirati shares have decreased 31% since the beginning of the year. The stock has risen 17% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRTX at https://www.zacks.com/ap/MRTX

Automated Insights, source Associated Press News